Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19798085 | 1.00 | PTGS1 (0.34) | PTGS1PTGS2 | |
| SCHEMBL13043006 | 0.98 | PTGS1 (0.34) | PTGS1PTGS2 | |
| SCHEMBL1439702 | 0.94 | PTGS1 (0.33) | PTGS1PTGS2 | |
| SCHEMBL15131749 | 0.92 | PTGS1 (0.32) | PTGS1PTGS2 | |
| SCHEMBL12570113 | 0.92 | PTGS1 (0.32) | PTGS1PTGS2 | |
| SCHEMBL1079186 | 0.91 | PTGS1 (0.36) | PTGS1PTGS2 | |
| SCHEMBL19622363 | 0.91 | PTGS1 (0.36) | PTGS1PTGS2 | |
| SCHEMBL9906141 | 0.91 | PTGS1 (0.32) | PTGS1PTGS2 | |
| SCHEMBL12603970 | 0.90 | PTGS1 (0.35) | PTGS1PTGS2 | |
| SCHEMBL16903720 | 0.90 | PTGS1 (0.33) | PTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240191078-A1 | ULTRAVIOLET-RAY-CURABLE COMPOSITION AND USE THEREOF | DOW TORAY CO LTD (JP) | 2024-06-13 | — | — | US | claimed |
| US-20240174889-A1 | ULTRAVIOLET-CURABLE COMPOSITION AND USE THEREOF | DOW TORAY CO LTD (JP) | 2024-05-30 | — | — | US | claimed |
| CN-117203280-A | Ultraviolet curable composition and use thereof | 陶氏东丽株式会社 | 2023-12-08 | — | — | CN | claimed |
| CN-117136214-A | Ultraviolet curable composition and use thereof | 陶氏东丽株式会社 | 2023-11-28 | — | — | CN | claimed |
| WO-2022202498-A1 | ULTRAVIOLET-CURABLE COMPOSITION AND USE THEREOF | ダウ・東レ株式会社 | 2022-09-29 | — | — | WO | claimed |
| WO-2022203042-A1 | ULTRAVIOLET-RAY-CURABLE COMPOSITION AND USE THEREOF | ダウ・東レ株式会社 | 2022-09-29 | — | — | WO | claimed |
| US-20260022202-A1 | UV-CURABLE COMPOSITION AND USE THEREOF | DOW TORAY CO LTD (JP) | 2026-01-22 | — | — | US | disclosed |
| US-20250368774-A1 | ULTRAVIOLET-CURABLE COMPOSITION AND USE THEREOF | DOW TORAY CO LTD (JP) | 2025-12-04 | — | — | US | disclosed |
| CN-119968415-A | Ultraviolet curable composition and use thereof | 陶氏东丽株式会社 | 2025-05-09 | — | — | CN | disclosed |
| CN-119032098-A | Ultraviolet curable composition and use thereof | 陶氏东丽株式会社 | 2024-11-26 | — | — | CN | disclosed |
| US-20240191078-A1 | ULTRAVIOLET-RAY-CURABLE COMPOSITION AND USE THEREOF | DOW TORAY CO LTD (JP) | 2024-06-13 | — | — | US | disclosed |
| US-20240174889-A1 | ULTRAVIOLET-CURABLE COMPOSITION AND USE THEREOF | DOW TORAY CO LTD (JP) | 2024-05-30 | — | — | US | disclosed |
| WO-2024071133-A1 | UV-CURABLE COMPOSITION AND USE THEREOF | ダウ・東レ株式会社 | 2024-04-04 | — | — | WO | disclosed |
| CN-117203280-A | Ultraviolet curable composition and use thereof | 陶氏东丽株式会社 | 2023-12-08 | — | — | CN | disclosed |
| CN-117136214-A | Ultraviolet curable composition and use thereof | 陶氏东丽株式会社 | 2023-11-28 | — | — | CN | disclosed |
| WO-2023224118-A1 | ULTRAVIOLET-CURABLE COMPOSITION AND USE THEREOF | ダウ・東レ株式会社 | 2023-11-23 | — | — | WO | disclosed |
| WO-2022202498-A1 | ULTRAVIOLET-CURABLE COMPOSITION AND USE THEREOF | ダウ・東レ株式会社 | 2022-09-29 | — | — | WO | disclosed |
| WO-2022203042-A1 | ULTRAVIOLET-RAY-CURABLE COMPOSITION AND USE THEREOF | ダウ・東レ株式会社 | 2022-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260022202-A1 | UV-CURABLE COMPOSITION AND USE THEREOF | IDUA, SEM1, ARSA | PTGS1 2446/4885PTGS2 2894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.